GU Cancers 2021 | The adoption of ICI maintenance therapy in mUC in the US

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, describes a qualitative analysis presented at ASCO GU 2021 of treatment patterns in community oncology providers in the US, which aimed to evaluate the adoption of immune checkpoint inhibitors in front-line therapy for patients with advanced or metastatic urothelial carcinoma (mUC). This study demonstrated that the majority of providers implement standard of care disseminated from the JAVELIN Bladder 100 trial (NCT02603432), which involves platinum-based chemotherapy followed by switch maintenance avelumab immunotherapy in patients with advanced/mUC. This interview took place during the 2021 Genitourinary Cancers Symposium.